[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100648673":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":12,"responsibleParty":34,"collaborators":37,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":12,"eligibilityCriteria":47,"healthyVolunteers":48,"sex":49,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":12,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":12,"overallStatus":61,"whyStopped":12,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":12},{"fullName":5,"class":6},"University of Washington","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"SOC","NO_INTERVENTION","Standard of Care",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Intervention + SOC","ACTIVE_COMPARATOR","Standard of care plus feedback on adherence",[18],"Diagnostic Test: POC urine TFV test with DLFB",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":12},"DIAGNOSTIC_TEST","POC urine TFV test with DLFB","Women randomized to the intervention arm will take POC urine TFV tests and will receive drug level feedback (DLFB) alongside SOC counseling at each visit until exit.",[14],[26],{"name":27,"affiliation":5,"role":28},"Jennnifer Velloza, PhD, MPH","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":12,"phoneExt":12,"email":33},"Jennifer Morton","CONTACT","jfmorton@uw.edu",{"type":28,"investigatorFullName":35,"investigatorTitle":36,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"Jennifer Velloza","Affiliate Assistant Professor: School of Medicine, Global Health",[38],{"name":39,"class":40},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH","100648673","a-hybrid-effectiveness-implementation-trial-of-urine-point-of-care-assay-to-increase-prep-adherence-among-women-in-kenya-100648673",false,"NCT07725679","A Hybrid Effectiveness-Implementation Trial of Urine Point-of-Care Assay to Increase PrEP Adherence Among Women in Kenya","A Hybrid Effectiveness-Implementation Trial of a Urine Point-of-Care Assay to Increase PrEP Adherence Among Women in Kenya","Inclusion Criteria:\n\n* HIV uninfected\n* Received daily oral PrEP one month prior, with a negative result on a urine assay one-month post PrEP initiation\n* Currently attending or willing to attend one of the study clinics for PrEP refills\n* Interest in continuing on oral PrEP despite adherence challenges\n* No known sero-discordant relationships\n* Living in Kiambu County and not planning to relocate for the next year\n\nExclusion Criteria:\n\n* Inadequate capacity to consent or complete planned study procedures\n* Do not speak English or Kiswahili\n* Test positive for HIV at screening\n* Concomitant participation in another PrEP adherence support study",true,"FEMALE","18 Years","29 Years",{"count":53,"type":54},400,"ESTIMATED","INTERVENTIONAL",[57],"NA","The goal of this randomized trial study is to learn if drug-level feedback counseling works to improve oral PrEP adherence in adolescent girls and young women.\n\nResearchers will compare urine TFV assay positivity between arms. All participants will attend visits on the same schedule, and receive the same SOC counseling for PrEP adherence. Participants in the intervention arm will additionally take POC urine TFV tests and receive drug-level feedback as part of that counseling.",[60],"PrEP Adherence Monitoring","NOT_YET_RECRUITING","2026-07-21",{"date":64,"type":65},"2026-07-24","ACTUAL",{"date":67,"type":54},"2027-02-01",{"date":69,"type":54},"2031-08-01",{"name":5,"class":6}]